HM
APLS

Harvest Management’s Apellis Pharmaceuticals APLS Stock Holding History

Harvest Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,000
Closed -$419K – 49
2023
Q4 		$419K Buy
+7,000
New +$355K 0.39% 31
2023
Q3 		– Sell
-10,000
Closed -$911K – 53
2023
Q2 		$911K Buy
+10,000
New +$863K 0.79% 24

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Harvest Management's APLS Position: Q1 2026 in Review

Harvest Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 70,000 shares worth $2.82M. The stake represents 1.36% of the portfolio and ranks #17 among its holdings. This is a return to the name: Harvest Management previously reported a position in APLS as recently as Q1 2024.

Harvest Management first reported a position in APLS in Q2 2023 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Harvest Management held 70,000 shares of Apellis Pharmaceuticals worth $2.82M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Harvest Management position in Q1 2026.
  • Apellis Pharmaceuticals made up 1.36% of Harvest Management's portfolio in Q1 2026, its #17 holding.
  • Harvest Management first reported a position in Apellis Pharmaceuticals in Q2 2023 and has held it in 3 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Harvest Management's 13F filing for Q1 2026, filed 15 May 2026.